CEConversations

Creative Educational Concepts
  • 4,9 (30)
  • SCIENCES
  • DEUX FOIS PAR MOIS

Welcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.

  1. 28 JANV.

    The New Era of Hemophilia Treatment

    We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health, mental health, aging, and everyday habits that protect long‑term outcomes. • Non‑factor prophylaxis versus factor replacement and what each does best • Treating beyond dated trough targets toward durable thrombin generation • Matching therapy to activity level, joint status, and venous access • Why shared decision making beats one‑size‑fits‑all regimens • Practical plans for breakthrough bleeds and procedures • Aging, comorbidities, and proactive screening for liver cancer and heart disease • Weight, movement, physical therapy, and joint load reduction • Vitamin D, bone health, and osteoporosis risk • Chronic pain, anxiety, and skills to break rumination with breathwork • Caregiver choices for kids and the importance of evolving plans This webisode series will provide a review of non-factor prophylaxis therapies for patients with hemophilia A or B with or without inhibitors, as well as provide helpful insights on the roles of gene therapies, considering safety profiles and monitoring requirements, aligning treatment options with lifestyle and individual preferences, and how bleed plans change with the different prophylaxis therapies. These webisodes intend to help patients feel more prepared to engage the hemophilia care team in meaningful conversations that support shared decision-making in treatment planning: https://cmeo.me/PE-020

    46 min

  2. 01/10/2025

    MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

    Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings.  In this CEC Oncology live, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.  Learn More: https://www.ceconcepts.com/activity/save-the-date-mek-inhibitors-in-neurofibromatosis-type-1-nursing-contributions-to-nf1-pn-management/

    1 h 5 min

  3. 19/09/2025

    Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies

    | Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early signs of DTs, understanding novel systemic therapies like tyrosine kinase and gamma-secretase inhibitors, and managing their distinct adverse event (AE) profiles. As frontline providers in symptom management and patient counseling, these clinicians urgently need education on evidence-based strategies for monitoring and mitigating treatment-related toxicities. Targeted learning will empower nursing professionals to improve patient safety, support adherence, and deliver comprehensive, individualized care across the DT treatment continuum.  In this CE Concepts recorded symposium, expert faculty will guide learners to identify features and challenges of early diagnosis and treatment of DTs, evaluate the use of novel targeted therapies, and implement evidence-based strategies to monitor and manage AEs associated with systemic therapies for DTs to improve patient safety and adherence. Learn More:https://www.ceconcepts.com/activity/desmoid-tumors-in-focus-early-recognition-evolving-therapies-and-nursing-led-care-strategies-2/

    55 min

  4. 19/09/2025

    The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

    | Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging clinical trial data into everyday practice, particularly in identifying candidates for mitogen-activated protein kinase inhibitors, managing adverse events, and coordinating multidisciplinary care. Limited experience with NF1 further contributes to gaps in long-term disease monitoring and personalized treatment planning. To close these gaps, clinicians must be equipped with practical, case-based strategies to improve early disease recognition, evidence-based management, and interprofessional collaboration that includes a team-based approach to address both clinical and psychosocial needs in the journey of patients with NF1.   In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.   Learn More: https://www.ceconcepts.com/activity/the-mektrix-decoding-the-real-world-impact-of-therapeutic-advances-in-neurofibromatosis-type-1-associated-plexiform-neurofibroma-management-across-pediatric-and-adult-populations-2/

    1 h 33 min

  5. 28/08/2025

    Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events

    As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutionized the treatment of hematological malignancies, they are also associated with symptoms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infection, and cardiotoxicity. While most cases of CRS and neurotoxicity are self-limiting and only require supportive care, some patients can progress to needing ICU care. To address these risks, EM clinicians require education on the relationship of MOAs of T-cell-directing therapies to potential AEs and improve their confidence and competence in diagnosing and treating CRS, neurotoxicity, and other toxicities associated with these agents in emergency settings. In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS.   Learn More: https://www.ceconcepts.com/activity/emergency-care-of-patients-with-cancer-receiving-car-t-cell-and-bispecific-antibody-immunotherapies-experiencing-serious-adverse-events/

    47 min

  6. 10/07/2025

    Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life

    In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population. To learn more: https://www.ceconcepts.com/activity/treating-metastatic-her2-negative-breast-cancer-oncology-nursing-approaches-to-improve-patient-quality-of-life/

    50 min

  7. 02/07/2025

    Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches

    In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, consider new treatment methods, and respect the unique needs of each patient. Find more details and collect credit here: https://www.ceconcepts.com/activity/advancing-cervical-cancer-care-navigating-new-therapies-guidelines-and-patient-centric-approaches-2/

    48 min

  8. 19/06/2025

    MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-World Applications in NF1-PN Management

    In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient’s lifespan. Request credit: https://www.ceconcepts.com/activity/mek-inhibitors-in-neurofibromatosis-type-1-latest-advances-and-real-world-applications-in-nf1-pn-management-2/

    1 h 4 min
Tout afficher (43)

4,9
sur 5
30 notes

À propos

Welcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.

Informations

  • Création
    Creative Educational Concepts
  • Années d’activité
    2021 - 2026
  • Épisodes
    43
  • Classification
    Tous publics
  • Copyright
    © 2026 CEConversations
  • Site web de l’émission
    CEConversations